<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04397913</url>
  </required_header>
  <id_info>
    <org_study_id>2020paracetamol-ibuprofen001</org_study_id>
    <nct_id>NCT04397913</nct_id>
  </id_info>
  <brief_title>Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Children With PDA</brief_title>
  <official_title>Population Pharmacokinetics and Dosage Individualization of Paracetamol and Ibuprofen in Preterm Neonates and Infants With Patent Ductus Arteriosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>West China Second University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigator's purpose is to study the population pharmacokinetics of paracatamol and
      ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of
      dosage individualization.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigator's purpose is to study the population pharmacokinetics of paracatamol and
      ibuprofen in neonates with patent ductus arteriosus (PDA) and assess the feasibility of
      dosage individualization. In this study, the investigator will detect drug concentration in
      plasma and other clinical test to construct population pharmacokinetic models.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">May 25, 2020</start_date>
  <completion_date type="Anticipated">May 6, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma drug concentration of paracetamol</measure>
    <time_frame>at (0-1) hour, (1-3) hours, (3-5) hours, (5-6) hours after oral administration</time_frame>
    <description>To detect the plasma concentration of paracetamol after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma drug concentration of ibuprofen</measure>
    <time_frame>at (0-1.5) hours, (1-4) hours, (4-12) hours,(12-24) hours after oral administration</time_frame>
    <description>To detect the plasma concentration of ibuprofen after administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Echocardiography</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>To measure arterial duct diameter, shunt speed and direction of shunt</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiac function</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>To detect brain natriuretic peptide(BNP) and troponin T(cTnT)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Through study completion, an average of 3 days</time_frame>
    <description>Drug-related adverse events and serious adverse events</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Patent Ductus Arteriosus</condition>
  <arm_group>
    <arm_group_label>Treatment(paracetamol or ibuprofen)</arm_group_label>
    <description>Paracetamol and ibuprofen are administered at standard dose for children with PDA.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paracetamol</intervention_name>
    <description>15 mg/kg, q6h</description>
    <arm_group_label>Treatment(paracetamol or ibuprofen)</arm_group_label>
    <other_name>Acetaminophen</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>10 mg/kg qd for the 1st day, 5 mg/kg qd for the 2nd and 3rd day</description>
    <arm_group_label>Treatment(paracetamol or ibuprofen)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Neonates with patent ductus arteriosus
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients have been diagnosed with PDA;

          -  Age: postnatal age â‰¤ 28 days;

          -  Paracetamol or ibuprofen used as part of regular treatment;

          -  Paracetamol or ibuprofen was administered orally.

        Exclusion Criteria:

          -  Patients who die within the treatment cycle;

          -  Patients with other heart diseases;

          -  Other factors that the researcher considers unsuitable for inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>28 Days</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wei Zhao, Ph.D</last_name>
    <phone>053188383308</phone>
    <email>zhao4wei2@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>West China Second University Hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Zhao, Ph.D</last_name>
      <phone>86053188383308</phone>
      <email>zhao4wei2@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 18, 2020</study_first_submitted>
  <study_first_submitted_qc>May 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>May 20, 2020</last_update_submitted>
  <last_update_submitted_qc>May 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Wei Zhao</investigator_full_name>
    <investigator_title>Professor; Head of department of clinical pharmacy and pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ductus Arteriosus, Patent</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

